| Similar Articles |
|---|
 |
The Motley Fool
June 28, 2005
Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.   |
The Motley Fool
March 22, 2004
Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool
January 13, 2004
Alyce Lomax |
CVS Fever Drug stores benefit from the flu bug, but for how much longer? |
The Motley Fool
July 6, 2007
Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool
June 10, 2004
Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool
July 6, 2004
Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool
June 2, 2004
Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool
July 5, 2005
Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool
September 27, 2004
Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool
March 9, 2004
Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool
January 7, 2010
Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
May 5, 2004
Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. |
The Motley Fool
July 6, 2007
Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool
July 6, 2004
Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool
August 15, 2005
Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool
April 9, 2007
Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
The Motley Fool
June 26, 2007
Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down. |
The Motley Fool
June 21, 2004
Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore. |
The Motley Fool
April 4, 2007
Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies. |
The Motley Fool
September 26, 2006
Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool
March 28, 2005
Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? |
The Motley Fool
January 4, 2008
Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool
December 23, 2003
Dave Marino-Nachison |
Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years. |
The Motley Fool
June 11, 2007
Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool
September 22, 2005
Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had. |
The Motley Fool
July 6, 2007
Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note. |
The Motley Fool
January 3, 2012
Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts. |
The Motley Fool
August 4, 2004
Phil Wohl |
CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size. |
The Motley Fool
January 3, 2012
Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses. |
The Motley Fool
June 25, 2004
Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool
May 9, 2005
Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note. |
The Motley Fool
September 24, 2004
Seth Jayson |
Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards. |
The Motley Fool
March 23, 2011
Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. |
The Motley Fool
December 26, 2006
Matthew Crews |
Walgreen Represents This drugstore business has proven itself; does its stock match up? |
The Motley Fool
September 14, 2006
Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool
October 8, 2011
Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. |
The Motley Fool
October 6, 2004
Steven Mallas |
Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage. |
The Motley Fool
September 27, 2005
Nathan Slaughter |
All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors. |
The Motley Fool
December 21, 2007
Timothy M. Otte |
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales. |
The Motley Fool
July 7, 2004
Steven Mallas |
CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be. |
The Motley Fool
October 4, 2005
Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool
January 4, 2005
Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool
June 10, 2010
Claire Stephanic |
CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers. |
The Motley Fool
December 11, 2006
Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note. |
The Motley Fool
September 22, 2006
Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool
July 29, 2011
Shubh Datta |
A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy. |
The Motley Fool
June 23, 2006
Rich Smith |
Foolish Forecast: Walgreen The retail pharmacy reports its fiscal third-quarter 2006 earnings on Monday. Investors -- buy, sell or waffle? |
The Motley Fool
September 29, 2010
Andrew Bond |
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters. |
The Motley Fool
March 24, 2011
Rick Aristotle Munarriz |
It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak. |
